ArticleAlimentary pharmacology & therapeutics2020

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.

Vera E R Asscher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.